rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastické činidlá - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
erlotinib stada 150 mg
stada arzneimittel ag, nemecko - erlotinib - 44 - cytostatica
erlotinib stada 100 mg
stada arzneimittel ag, nemecko - erlotinib - 44 - cytostatica
erlotinib teva 150 mg filmom obalené tablety
teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica
erlotinib teva 100 mg filmom obalené tablety
teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica
erlotinib teva b.v. 150 mg
teva b.v., holandsko - erlotinib - 44 - cytostatica
erlotinib teva b.v. 100 mg
teva b.v., holandsko - erlotinib - 44 - cytostatica
erlotinib zentiva 150 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica
erlotinib zentiva 100 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica
erlotinib zentiva 25 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica